← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV18행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 2
AL3818 (AL3818)
Sarcoma Oncology Research Center, …·Solid Tumor, Adult
58 trials
Overview
Program
AL3818
Overview
Company
Sarcoma Oncology Research Center, LLC
Overview
Modality
ANTIBODY
Overview
Target
Solid Tumor, Adult
Overview
Indication
Solid Tumor, Adult; Soft Tissue Sarcoma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Mechanism
target tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor
MoA
Biomarker
Biomarkers of oxidative stress were measured by corresponding kit
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
Self-assembled copper-based nanoparticles for enzyme catalysis-enhanced chemodynamic/photodynamic/antiangiogenic tritherapy against hepatocellular carcinoma.. As an emerging cancer treatment strategy, reactive oxygen species-based tumor catalytic therapies face enormous challenges due to hypoxia and the overexpression of glutathione (GSH) in the tumor microenvironment. Herein, a self-assembled cop…
Clinical
Data Tier / Score
A · 34
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 13일 (1일 전)